How does DMPK help in drug profiling and drug safety of the new drug entity
DMPK studies helps in the understanding of pharmacokinetic properties of the drug compound to validate and assess the drug safety and profile of the drug compound. This helps in the drug development process to evaluate and understand how the drug is cleared from the body after being administered into the body without producing toxic metabolites or showing adverse side effects. DMPK analysis is done throughout the drug discovery phases.
How does it help in drug profiling and safety of new drug molecules?
DMPK studies involve process optimization techniques that require experimental validation of data involving solubility, permeability, metabolism and drug to drug interactions that can affect the safety and efficacy of the new drug entity. It mainly involves the Absorption, Distribution, Metabolism and Excretion (ADME) analysis of the drug compound. ADME studies are carried out with in vitro and in vivo methods.
In vitro models account for the ADME parameters that involve study of permeability, metabolic stability, phenotyping, protein binding technique, drug to drug interaction potentials, cell proliferation and cytotoxicity.
It helps in assessing the factors like bioavailability and drug–drug interactions (DDI) and validates the properties like clearance, half-life, distribution volume and metabolic profile.
DMPK studies provide structural transformation by understanding its pharmacokinetic properties. Validating and studying the nature of drug enzymes, transporters, inhibitors and induction would reduce the potential DDI which in turn would reduce the attrition for the safety profiles and efficacy of the drug.
Pharmacokinetic and blood brain barrier studies give interpretation for preclinical toxicological data and efficacy. Also, the studies give the understanding of mechanisms of drug activities and optimization in drug discovery methods. It also helps in the assessment of dosage, design module and clinical advantages and procedures.
Drug metabolizing enzymes and transporters play a vital role in understanding the regulatory mechanisms governed in the studies. Nuclear receptors and non-coding RNAs that form a part of transcriptional and post transcriptional factors decide the modulation of DMPK studies. The drug metabolism and bioanalysis studies give the proper estimation of DDI, toxicological results and therapeutic indices through the assessment of in vitro and in vivo pharmacokinetic studies. Pharmacological assessment is necessary for the lead optimization during the drug development process to elucidate the structure activity relationships (SAR) and structure property relationships (SPR). The pharmacokinetic properties verify the ADME datas regarding the drugs bioavailability and short half-life.
The good DMPK profile reduces the risk factors associated with drug delivery systems. Sometimes the oral administration can result in poor absorption and bioavailability and hence a poor DMPK profile can decrease the therapeutic efficacy of the drug.
Drug development and discovery methods have been improved over the years by using the latest techniques and tools used for the evaluation of the DMPK properties and studies. For the process optimization techniques, DMPK properties have been formatted, improved and applied in the drug delivery and development strategy to affect the development strategy.